Comparative Pharmacology
Head-to-head clinical analysis: MAXAIR versus OXTRIPHYLLINE PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXAIR versus OXTRIPHYLLINE PEDIATRIC.
MAXAIR vs OXTRIPHYLLINE PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular cAMP.
Xanthine derivative that inhibits phosphodiesterase, increasing cyclic AMP levels; antagonizes adenosine receptors, leading to bronchodilation, central nervous system stimulation, and positive inotropic effects.
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
200 mg orally every 6-8 hours; extended-release: 400-600 mg orally every 12 hours.
None Documented
None Documented
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Neonates: 24-36 hours; Infants 1-6 months: 14-29 hours; Children 6-12 months: 9-18 hours; Children 1-9 years: 3-6 hours; Adults: 7-12 hours. Half-life prolonged in hepatic impairment, CHF, and COPD.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Renal (70-80% as unchanged drug, 10-15% as metabolites); biliary/fecal (<10%)
Category C
Category C
Bronchodilator
Bronchodilator